LOVASTATIN/TICAGRELOR [VA Drug Interaction]
Conditions
Brief summary
The purpose of this study is to determine ticagrelor combining with low molecular weight heparin is effective and safe during PCI or not.
Detailed description
Ticagrelor is a new drug compared with clopidogrel. It has a stronger antiplatelet capacity. After PCI，whether using low molecular weight heparin can make patients better prognosis or not, What's more，full amount or half amount low molecular weight heparin?, also investigators want to explore that whether it may lead to more bleeding events.
Interventions
DRUGTicagrelor
Patients were treated with full amount low molecular weight heparin randomly after PCI,All patients are treated with ticagrelor one year.
DRUGfull amount low molecular weight heparin
Patients were treated with half amount low molecular weight heparin randomly after PCI,All patients are treated with ticagrelor one year.
DRUGhalf amount low molecular weight heparin
Patients were treated with half amount low molecular weight heparin randomly after PCI,All patients are treated with ticagrelor one year.
DRUGNo low molecular weight heparin
Patients were treated with no low molecular weight heparin randomly after PCI,All patients are treated with ticagrelor one year.
Sponsors
Beijing Anzhen Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Age ≥18 years old and ≤75 years ; 2. unstable angina, non-ST segment elevation acute myocardial infarction, old myocardial infarction, or confirm the presence of myocardial ischemia; 3. voluntary participation in clinical trials, and informed consent;
Exclusion criteria
1. acute ST segment elevation myocardial infarction, stable angina pectoris; 2. aspirin allergy or resistance; 3. consolidated stroke, chronic obstructive pulmonary disease and other ticagrelor contraindications; 4. patients have coagulopathy; 5. can not be continued for one year with aspirin and treatment of dual antiplatelet ticagrelor; 6. can not complete revascularization; 7. NYHA ≥Ⅲ level or left ventricular ejection fraction \<40%; 8. severe liver and kidney dysfunction (ALT and AST were more than three times the upper limit of normal, creatinine clearance less than 30ml / min-1.1.72m-2);
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| all cause mortality | one year |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Nonfatal myocardial infarction | one year | Patients occur acute myocardial infarction in a year，but it could not lead to die. |
| Non-fatal stroke | one year | Patients occur stroke in a year，but it could not lead to die. |
| Revascularization again | one year | Coronary arteries occur stenosis again in a year，the patients are treated with revascularization，including PCI and CABG. |
| Rehospitalization for ACS or heart failure | one year | Patients are hospitalized again because of ACS or heart failure in a year. |
| Bleeding events | one year | assessing the bleeding events according the TIMI grade. |
Countries
China
Outcome results
None listed